Ruben Sanchez Email

VP Regulatory Affairs . CG Oncology

Current Roles

Employees:
82
Revenue:
$12.7M
About
CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in multiple clinical programs, including ongoing trials with CG0070 as a monotherapy in a global Phase 3 study (BOND3) for the treatment of BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), and also in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 study (CORE1) in the same indication. Additional indications in muscle-invasive bladder cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.
CG Oncology Address
400 Spectrum Center Drive
Irvine, CA
United States
CG Oncology Email

Past Companies

CG OncologyVice President Regulatory Affairs
Revance Therapeutics, Inc.Sr. Director, Regulatory Affairs
SillaJen Inc.Sr. Director Regulatory Affairs

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.